Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Dubovsky

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Expert Review of Vaccines|February 3, 2006
Meeting on planning Plasmodium vivax vaccine efficacy trials. July 20-21, 2004, SingaporeVassee Moorthy, Filip Dubovsky
Trends in Parasitology|May 19, 2006
Progress towards the development of malaria vaccinesElissa Malkin, Filip Dubovsky, Melinda Moree
Human Vaccines|June 27, 2009
Challenges in developing a pediatric RSV vaccineJeanne H Schickli, Filip Dubovsky, Roderick S Tang
Vaccine|October 11, 2011
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adultsStan L Block, Tingting Yi, Eric Sheldon, et al.
Vaccine|June 13, 2006
Potency assay design for adjuvanted recombinant proteins as malaria vaccinesBirgitte K Giersing, Filip Dubovsky, Allan Saul, et al.
The Pediatric Infectious Disease Journal|September 20, 2011
Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative childrenDavid I Bernstein, Elissa Malkin, Nazha Abughali, et al.
The Pediatric Infectious Disease Journal|June 2, 2009
Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive childrenMargarita Gomez, Maurice A Mufson, Filip Dubovsky, et al.
Biologicals : Journal of the International Association of Biological Standardization|August 29, 2017
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteersRaburn M Mallory, S Omar Ali, Therese Takas, et al.
Vaccine|December 5, 2019
A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of ageRaburn M Mallory, Andrew Nyborg, Rubana N Kalyani, et al.
Influenza and Other Respiratory Viruses|March 25, 2018
The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studiesRaburn M Mallory, Jing Yu, Sachiko Kameo, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Expert Review of Vaccines|February 3, 2006
Meeting on planning Plasmodium vivax vaccine efficacy trials. July 20-21, 2004, SingaporeVassee Moorthy, Filip Dubovsky
Trends in Parasitology|May 19, 2006
Progress towards the development of malaria vaccinesElissa Malkin, Filip Dubovsky, Melinda Moree
Human Vaccines|June 27, 2009
Challenges in developing a pediatric RSV vaccineJeanne H Schickli, Filip Dubovsky, Roderick S Tang
Vaccine|October 11, 2011
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adultsStan L Block, Tingting Yi, Eric Sheldon, et al.
Vaccine|June 13, 2006
Potency assay design for adjuvanted recombinant proteins as malaria vaccinesBirgitte K Giersing, Filip Dubovsky, Allan Saul, et al.
The Pediatric Infectious Disease Journal|September 20, 2011
Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative childrenDavid I Bernstein, Elissa Malkin, Nazha Abughali, et al.
The Pediatric Infectious Disease Journal|June 2, 2009
Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive childrenMargarita Gomez, Maurice A Mufson, Filip Dubovsky, et al.
Biologicals : Journal of the International Association of Biological Standardization|August 29, 2017
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteersRaburn M Mallory, S Omar Ali, Therese Takas, et al.
Vaccine|December 5, 2019
A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of ageRaburn M Mallory, Andrew Nyborg, Rubana N Kalyani, et al.
Influenza and Other Respiratory Viruses|March 25, 2018
The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studiesRaburn M Mallory, Jing Yu, Sachiko Kameo, et al.
Pageof 6